Study finds benefits listed in larger text than risks in mags

Share this article:
A study of oncology drug ads in the magazines CURE, Coping With Cancer and MAMM found benefits presented more prominently and in larger text than risks. The study, presented to the American Society of Clinical Oncology's annual meeting, found that while benefits usually placed in the top third of the ad space, risks were often presented in smaller type and relegated to the lower half of the page.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.